- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00516698
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy
RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of breast cancer in the future.
PURPOSE: This clinical trial is studying changes in breast density and blood hormone levels in postmenopausal women receiving anastrozole or exemestane for breast cancer.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
OBJECTIVES:
- To assess the changes in percent breast density (in response to 1 year of aromatase inhibitor therapy) from levels prior to the initiation of treatment.
- To assess the changes in dense area (in response to 1 year of aromatase inhibitor therapy) from levels prior to the initiation of treatment.
- To examine whether changes in percent breast density (in response to 1 year of aromatase inhibitor therapy) from pre-treatment levels correlate with changes in plasma hormone levels (estrone, estrone-sulfate, estradiol, and SHBG) and drug levels (anastrozole or exemestane) over the same time period.
- To examine whether changes in dense area (in response to 1 year of aromatase inhibitor therapy) from pre-treatment mammogram correlate with changes in plasma hormone levels (estrone, estrone-sulfate, estradiol, and SHBG) and drug levels (anastrozole or exemestane) over the same time period.
- To assess whether women with high pre-treatment percent density (upper tertile) experience greater decreases in percent breast density after 1 year of aromatase inhibitor therapy than women with low pre-treatment percent density (lower tertile).
- To assess whether women with high pre-treatment dense area (upper tertile) experience greater decreases in dense area after 1 year of aromatase inhibitor therapy than women with low pre-treatment dense area (lower tertile).
- To examine the associations of haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway identified through the Mayo Clinic and Indiana University Pharmacogenomics Research Network Projects, with changes in percent and area density, plasma hormone levels, and drug levels after 1 year of aromatase inhibitor therapy.
OUTLINE: This is a multicenter study.
Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.
Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Georgia
-
Augusta, Georgia, Stati Uniti, 30912
- MBCCOP - Medical College of Georgia Cancer Center
-
-
Illinois
-
Aurora, Illinois, Stati Uniti, 60504
- Rush-Copley Cancer Care Center
-
Bloomington, Illinois, Stati Uniti, 61701
- St. Joseph Medical Center
-
Canton, Illinois, Stati Uniti, 61520
- Graham Hospital
-
Carthage, Illinois, Stati Uniti, 62321
- Memorial Hospital
-
Effingham, Illinois, Stati Uniti, 62401
- St. Anthony's Memorial Hospital
-
Eureka, Illinois, Stati Uniti, 61530
- Eureka Community Hospital
-
Galesburg, Illinois, Stati Uniti, 61401
- Galesburg Cottage Hospital
-
Galesburg, Illinois, Stati Uniti, 61401
- Galesburg Clinic, PC
-
Havana, Illinois, Stati Uniti, 62644
- Mason District Hospital
-
Hopedale, Illinois, Stati Uniti, 61747
- Hopedale Medical Complex
-
Joliet, Illinois, Stati Uniti, 60435
- Joliet Oncology-Hematology Associates, Limited - West
-
Macomb, Illinois, Stati Uniti, 61455
- Mcdonough District Hospital
-
Moline, Illinois, Stati Uniti, 61265
-
Moline, Illinois, Stati Uniti, 61265
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
-
Normal, Illinois, Stati Uniti, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, Stati Uniti, 61761
- Community Cancer Center
-
Ottawa, Illinois, Stati Uniti, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, Stati Uniti, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, Stati Uniti, 61554
- Cancer Treatment Center at Pekin Hospital
-
Peoria, Illinois, Stati Uniti, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Stati Uniti, 61614
- Proctor Hospital
-
Peoria, Illinois, Stati Uniti, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, Stati Uniti, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, Stati Uniti, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, Stati Uniti, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, Stati Uniti, 61356
- Perry Memorial Hospital
-
Spring Valley, Illinois, Stati Uniti, 61362
- St. Margaret's Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center at Carle Foundation Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Beech Grove, Indiana, Stati Uniti, 46107
- St. Francis Hospital and Health Centers - Beech Grove Campus
-
Michigan City, Indiana, Stati Uniti, 46360
- Saint Anthony Memorial Health Centers
-
Richmond, Indiana, Stati Uniti, 47374
- Reid Hospital & Health Care Services
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- McFarland Clinic, PC
-
Bettendorf, Iowa, Stati Uniti, 52722
-
Des Moines, Iowa, Stati Uniti, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Stati Uniti, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Stati Uniti, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, Stati Uniti, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Des Moines, Iowa, Stati Uniti, 50307
- Mercy Capitol Hospital
-
Mason City, Iowa, Stati Uniti, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Sioux City, Iowa, Stati Uniti, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, Stati Uniti, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, Stati Uniti, 51104
- Mercy Medical Center - Sioux City
-
-
Kansas
-
Chanute, Kansas, Stati Uniti, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, Stati Uniti, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, Stati Uniti, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Kingman, Kansas, Stati Uniti, 67068
- Cancer Center of Kansas, PA - Kingman
-
Liberal, Kansas, Stati Uniti, 67901
- Southwest Medical Center
-
Newton, Kansas, Stati Uniti, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, Stati Uniti, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, Stati Uniti, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, Stati Uniti, 67042
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, Stati Uniti, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, Stati Uniti, 67214
- Wesley Medical Center
-
Wichita, Kansas, Stati Uniti, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, Stati Uniti, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, Stati Uniti, 67214
- CCOP - Wichita
-
Wichita, Kansas, Stati Uniti, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, Stati Uniti, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, Stati Uniti, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Adrian, Michigan, Stati Uniti, 49221
- Hickman Cancer Center at Bixby Medical Center
-
Lambertville, Michigan, Stati Uniti, 48144
- Haematology-Oncology Associates of Ohio and Michigan, PC
-
Monroe, Michigan, Stati Uniti, 48162
- Community Cancer Center of Monroe
-
Monroe, Michigan, Stati Uniti, 48162
- Mercy Memorial Hospital - Monroe
-
-
Minnesota
-
Bemidji, Minnesota, Stati Uniti, 56601
- MeritCare Bemidji
-
Burnsville, Minnesota, Stati Uniti, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, Stati Uniti, 55805
- CCOP - Duluth
-
Duluth, Minnesota, Stati Uniti, 55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth, Minnesota, Stati Uniti, 55805
- Miller - Dwan Medical Center
-
Edina, Minnesota, Stati Uniti, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Stati Uniti, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, Stati Uniti, 55350
- Hutchinson Area Health Care
-
Lichfield, Minnesota, Stati Uniti, 55355
- Meeker County Memorial Hospital
-
Mankato, Minnesota, Stati Uniti, 56002
- Immanuel St. Joseph's
-
Maplewood, Minnesota, Stati Uniti, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, Stati Uniti, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, Stati Uniti, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, Stati Uniti, 55102
- United Hospital
-
Saint Paul, Minnesota, Stati Uniti, 55102
- HealthEast Cancer Care at St. Joseph's Hospital
-
Shakopee, Minnesota, Stati Uniti, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
St. Paul, Minnesota, Stati Uniti, 55101
- Regions Hospital Cancer Care Center
-
Waconia, Minnesota, Stati Uniti, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, Stati Uniti, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
Woodbury, Minnesota, Stati Uniti, 55125
- HealthEast Cancer Care at Woodwinds Health Campus
-
-
Missouri
-
Saint Louis, Missouri, Stati Uniti, 63131
- Missouri Baptist Cancer Center
-
Saint Louis, Missouri, Stati Uniti, 63141
- Arch Medical Services, Incorporated at Center for Cancer Care and Research
-
-
Montana
-
Billings, Montana, Stati Uniti, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, Stati Uniti, 59101
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Billings, Montana, Stati Uniti, 59101
- Northern Rockies Radiation Oncology Center
-
Billings, Montana, Stati Uniti, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, Stati Uniti, 59107-7000
- Billings Clinic - Downtown
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, Stati Uniti, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, Stati Uniti, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, Stati Uniti, 59405
-
Helena, Montana, Stati Uniti, 59601
- St. Peter's Hospital
-
Kalispell, Montana, Stati Uniti, 59901
- Kalispell Regional Medical Center
-
Kalispell, Montana, Stati Uniti, 59901
- Glacier Oncology, PLLC
-
Kalispell, Montana, Stati Uniti, 59901
- Kalispell Medical Oncology at KRMC
-
Missoula, Montana, Stati Uniti, 59801
- Community Medical Center
-
Missoula, Montana, Stati Uniti, 59804
- Guardian Oncology and Center for Wellness
-
Missoula, Montana, Stati Uniti, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, Stati Uniti, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Carolina
-
Rutherfordton, North Carolina, Stati Uniti, 28139
- Rutherford Hospital
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Bismarck Cancer Center
-
Bismarck, North Dakota, Stati Uniti, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, Stati Uniti, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, Stati Uniti, 58502
- St. Alexius Medical Center Cancer Center
-
Fargo, North Dakota, Stati Uniti, 58122
- CCOP - MeritCare Hospital
-
Fargo, North Dakota, Stati Uniti, 58122
- MeritCare Broadway
-
-
Ohio
-
Bellefontaine, Ohio, Stati Uniti, 43311
- Mary Rutan Hospital
-
Bowling Green, Ohio, Stati Uniti, 43402
- Wood County Oncology Center
-
Chillicothe, Ohio, Stati Uniti, 45601
- Adena Regional Medical Center
-
Columbus, Ohio, Stati Uniti, 43214-3998
- Riverside Methodist Hospital Cancer Care
-
Columbus, Ohio, Stati Uniti, 43222
- Mount Carmel Health - West Hospital
-
Columbus, Ohio, Stati Uniti, 43215
- CCOP - Columbus
-
Columbus, Ohio, Stati Uniti, 43215
- Grant Medical Center Cancer Care
-
Columbus, Ohio, Stati Uniti, 43228
- Doctors Hospital at Ohio Health
-
Dayton, Ohio, Stati Uniti, 45405
- Grandview Hospital
-
Dayton, Ohio, Stati Uniti, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, Stati Uniti, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, Stati Uniti, 45429
- CCOP - Dayton
-
Delaware, Ohio, Stati Uniti, 43015
- Grady Memorial Hospital
-
Elyria, Ohio, Stati Uniti, 44035
- Hematology Oncology Center
-
Findlay, Ohio, Stati Uniti, 45840
- Blanchard Valley Medical Associates
-
Franklin, Ohio, Stati Uniti, 45005-1066
- Middletown Regional Hospital
-
Kettering, Ohio, Stati Uniti, 45429
- Charles F. Kettering Memorial Hospital
-
Lancaster, Ohio, Stati Uniti, 43130
- Fairfield Medical Center
-
Lima, Ohio, Stati Uniti, 45804
- Lima Memorial Hospital
-
Marietta, Ohio, Stati Uniti, 45750
- Strecker Cancer Center at Marietta Memorial Hospital
-
Maumee, Ohio, Stati Uniti, 43537
- Northwest Ohio Oncology Center
-
Maumee, Ohio, Stati Uniti, 43537
- St. Luke's Hospital
-
Newark, Ohio, Stati Uniti, 43055
- Licking Memorial Cancer Care Program at Licking Memorial Hospital
-
Oregon, Ohio, Stati Uniti, 43616
- St. Charles Mercy Hospital
-
Oregon, Ohio, Stati Uniti, 43616
- Toledo Clinic - Oregon
-
Sandusky, Ohio, Stati Uniti, 44870
- Firelands Regional Medical Center
-
Sandusky, Ohio, Stati Uniti, 44870
- North Coast Cancer Care, Incorporated
-
Springfield, Ohio, Stati Uniti, 45505
- Community Hospital of Springfield and Clark County
-
Springfield, Ohio, Stati Uniti, 45504
- Mercy Medical Center
-
Sylvania, Ohio, Stati Uniti, 43560
- Flower Hospital Cancer Center
-
Tiffin, Ohio, Stati Uniti, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, Stati Uniti, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, Stati Uniti, 43606
- Toledo Hospital
-
Toledo, Ohio, Stati Uniti, 43614
- Medical University of Ohio Cancer Center
-
Toledo, Ohio, Stati Uniti, 43617
- CCOP - Toledo Community Hospital
-
Toledo, Ohio, Stati Uniti, 43623
- Toledo Clinic, Incorporated - Main Clinic
-
Troy, Ohio, Stati Uniti, 45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wauseon, Ohio, Stati Uniti, 43567
- Fulton County Health Center
-
Westerville, Ohio, Stati Uniti, 43081
- Mount Carmel St. Ann's Cancer Center
-
Wilmington, Ohio, Stati Uniti, 45177
- Clinton Memorial Hospital
-
Xenia, Ohio, Stati Uniti, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
Zanesville, Ohio, Stati Uniti, 43701
- Genesis - Good Samaritan Hospital
-
-
Oklahoma
-
Tulsa, Oklahoma, Stati Uniti, 74136
- Natalie Warren Bryant Cancer Center at St. Francis Hospital
-
-
Pennsylvania
-
Danville, Pennsylvania, Stati Uniti, 17822-0001
- Geisinger Cancer Institute at Geisinger Health
-
Hazleton, Pennsylvania, Stati Uniti, 18201
- Geisinger Hazleton Cancer Center
-
State College, Pennsylvania, Stati Uniti, 16801
- Geisinger Medical Group - Scenery Park
-
Wilkes-Barre, Pennsylvania, Stati Uniti, 18711
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
-
Wilkes-Barre, Pennsylvania, Stati Uniti, 18765
- Mercy Hospital at Wilkes-Barre
-
-
South Carolina
-
Anderson, South Carolina, Stati Uniti, 29621
- AnMed Cancer Center
-
Spartanburg, South Carolina, Stati Uniti, 29303
- CCOP - Upstate Carolina
-
Spartanburg, South Carolina, Stati Uniti, 29303
- Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, Stati Uniti, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Virginia
-
Fredericksburg, Virginia, Stati Uniti, 22401
- Fredericksburg Oncology, Incorporated
-
-
Washington
-
Kirkland, Washington, Stati Uniti, 98033
- Cascade Cancer Center at Evergreen Hospital Medical Center
-
Port Angeles, Washington, Stati Uniti, 98362
- Olympic Medical Center
-
Renton, Washington, Stati Uniti, 98055
- Southlake Clinic
-
Seattle, Washington, Stati Uniti, 98101
- Virginia Mason Medical Center
-
Seattle, Washington, Stati Uniti, 98101
- CCOP - Virginia Mason Research Center
-
-
Wyoming
-
Sheridan, Wyoming, Stati Uniti, 82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
DISEASE CHARACTERISTICS:
Inclusion criteria:
Must have histologically confirmed invasive breast cancer, as defined by the following TNM staging criteria:
- pT1, pT2, or pT3
pNx, pN0, pN1, pN2, or pN3*
- Patients with positive sentinel node biopsies (pN1) must have subsequent axillary dissection to be eligible
- Patients with negative sentinel node biopsies (pN0) do not require axillary surgery for study eligibility
M0, according to the following radiologic studies:
Bone scan (required only if alkaline phosphatase is > 2 x institutional upper limit of normal [ULN] and/or there are symptoms of metastatic disease)
- A confirmatory x-ray or other imaging study, such as CT scan or MRI, is required if the results from the bone scan are questionable
- Abdominal ultrasound or CT scan of the abdomen (required only if AST/ALT or alkaline phosphatase is > 2 x ULN unless the elevation is in the bone fraction)
- Chest x-ray NOTE: *Only when the sole basis for this classification is the presence of 10 or more involved axillary nodes
Completely resected disease
- Surgical margins must be clear of invasive carcinoma and ductal carcinoma in situ or lobular carcinoma in situ
Must have one intact, noncancerous breast with no history of previous breast surgery in that breast (other than a breast biopsy)
- Mammogram of the intact, noncancerous breast required ≤ 6 months prior to study registration (both a craniocaudal [top down] and mediolateral oblique view [side view] must be available)
Must be registered on this study ≥ 3 weeks but ≤ 3 months after completion of chemotherapy OR primary surgery*
- Adjuvant chemotherapy and radiation therapy as prescribed by the local institution is allowed provided patient is registered on this study and hormonal treatment is begun as soon as patient has sufficiently recovered from chemotherapy NOTE: *Primary surgery is defined as the last surgical procedure to remove invasive or in situ disease
- Planning to receive anastrozole or exemestane for ≥ 1 year for treatment of breast cancer
Hormone receptor status:
- Estrogen receptor- and/or progesterone receptor-positive (defined as a tumor receptor content of > 10 fmol/mg protein OR receptor-positive by immunohistochemistry [ERICA or PgRICA])
PATIENT CHARACTERISTICS:
Inclusion criteria:
- Female
Postmenopausal, defined by one of the following:
- Age > 60 years
- Age 45-59 years with spontaneous cessation of menses > 12 months prior to chemotherapy (if no chemotherapy was given, then prior to study registration)
- Age 45-59 years with cessation of menses for a duration of < 12 months or secondary to hysterectomy AND an FSH level in the postmenopausal range (or ≥ 34.4 IU/L, if institutional range is not available) prior to chemotherapy (if no chemotherapy was given, then prior to study registration)
- Age 45-59 years with an FSH level in the postmenopausal range according to institutional laboratory standards (or > 34.4 IU/L, if the institutional range is not available) prior to chemotherapy (if no chemotherapy was given, then prior to study registration)
- Bilateral oophorectomy
- ECOG performance status 0, 1, or 2
- Life expectancy ≥ 5 years
Exclusion criteria:
- History of other (non-breast) malignancies, except adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, or other curatively treated solid tumors with no evidence of disease for > 5 years
- Any co-existing medical or psychiatric condition that is likely to interfere with study procedures and/or results
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- See Disease Characteristics
Exclusion criteria:
- Hormone replacement therapy, oral contraceptives, tamoxifen, raloxifene, other selective estrogen-receptor modulators, or gonadotropin releasing-hormone analogues ≤ 6 months prior to the pre-registration mammogram
- Prior treatment with an aromatase inhibitor (e.g., anastrozole, exemestane, letrozole)
- Planned surgery (other than core needle biopsy) to intact non-cancerous breast (e.g., preventive/prophylactic mastectomy)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Group 1
Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined. Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Changes in percent breast density in response to 1 year of aromatase inhibitor therapy
Lasso di tempo: Up to 12 months
|
Up to 12 months
|
Changes in dense area in response to 1 year of aromatase inhibitor therapy
Lasso di tempo: Up to 12 months
|
Up to 12 months
|
Correlation of changes in percent breast density with changes in plasma hormone levels and drug levels
Lasso di tempo: Up to 12 months
|
Up to 12 months
|
Correlation of changes in dense area with changes in plasma hormone levels and drug levels
Lasso di tempo: Up to 12 months
|
Up to 12 months
|
Comparison of percent breast density in women with high pre-treatment percent density vs women with low pre-treatment percent density
Lasso di tempo: Up to 12 months
|
Up to 12 months
|
Comparison of dense area in women with high pre-treatment dense area vs women with low pre-treatment dense area
Lasso di tempo: Up to 12 months
|
Up to 12 months
|
Associations of haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway with changes in percent and area density, plasma hormone levels, and drug levels after 1 year of aromatase inhibitor therapy
Lasso di tempo: Up to 12 months
|
Up to 12 months
|
Collaboratori e investigatori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NCCTG-N063I
- NCI-2012-02719 (Identificatore di registro: CTRP (Clinical Trials Reporting System))
- CDR0000560200 (Identificatore di registro: PDQ (Physician Data Query))
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro al seno
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University e altri collaboratoriCompletatoLa guida all'applicazione clinica di Conebeam Breast CTCina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Stati Uniti, Singapore, Canada
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
Prove cliniche su analisi del polimorfismo
-
Vanderbilt University Medical Center4DMedicalCompletato
-
University of MiamiAttivo, non reclutante
-
Universidad Miguel Hernandez de ElcheInstitut Català de la Salut; Andaluz Health Service; Osakidetza; Servicio Madrileño... e altri collaboratoriCompletatoMalattie professionaliSpagna
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... e altri collaboratoriCompletatoMalattia cardiovascolare | Carenza di vitamina D | Condizioni correlate alla menopausaBrasile